Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy
- PMID: 28694026
- DOI: 10.1016/j.addr.2017.07.003
Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy
Abstract
Nitrogen containing bisphosphonates (N-BPs) including zoledronate (ZOL) and alendronate (ALD) inhibit farnesyl diphosphate synthase, and have been shown to have a cytotoxic affect against cancer cells as a monotherapy and to also sensitise tumour cells to destruction by γδ T cells. γδ T cells are a subset of human T lymphocytes and have a diverse range of roles in the immune system including the recognition and destruction of cancer cells. This property of γδ T cells can be harnessed for use in cancer immunotherapy through in vivo expansion or the adoptive transfer of ex vivo activated γδ T cells. The use of N-BPs with γδ T cells has been shown to have a synergistic effect in in vitro, animal and clinical studies. N-BPs have limited in vivo activity due to rapid clearance from the circulation. By encapsulating N-BPs in liposomes (L) it is possible to increase the levels of N-BPs at non-osseous tumour sites. L-ZOL and L-ALD have been shown to have different toxicological profiles than free ZOL or ALD. Both L-ALD and L-ZOL led to increased spleen weight, leucocytosis, neutrophilia and lymphocytopenia in mice after intravenous injection. L-ALD was shown to be better tolerated than L-ZOL in murine studies. Biodistribution studies have been performed in order to better understand the interaction of N-BPs and γδ T cells in vivo. Additionally, in vivo therapy studies have shown that mice treated with both L-ALD and γδ T cells had a significant reduction in tumour growth compared to mice treated with L-ALD or γδ T cells alone. The use of ligand-targeted liposomes may further increase the efficacy of this combinatory immunotherapy. Liposomes targeting the αvβ6 integrin receptor using the peptide A20FMDV2 had a greater ability than untargeted liposomes in sensitising cancer cells to destruction by γδ T cells in αvβ6 positive cancer cell lines.
Keywords: Alendronic acid; Biphosphonate; Gamma delta T cells; Immunotherapy; Liposomes; Zoledronic acid.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.J Control Release. 2016 Nov 10;241:229-241. doi: 10.1016/j.jconrel.2016.09.023. Epub 2016 Sep 21. J Control Release. 2016. PMID: 27664328 Free PMC article.
-
Investigating in vitro and in vivo αvβ6 integrin receptor-targeting liposomal alendronate for combinatory γδ T cell immunotherapy.J Control Release. 2017 Jun 28;256:141-152. doi: 10.1016/j.jconrel.2017.04.025. Epub 2017 Apr 18. J Control Release. 2017. PMID: 28432037 Free PMC article.
-
Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid.Cancer Sci. 2013 May;104(5):536-42. doi: 10.1111/cas.12124. Epub 2013 Mar 19. Cancer Sci. 2013. PMID: 23387443 Free PMC article.
-
Cancer immunotherapy harnessing γδ T cells and programmed death-1.Immunol Rev. 2020 Nov;298(1):237-253. doi: 10.1111/imr.12917. Epub 2020 Sep 5. Immunol Rev. 2020. PMID: 32888218 Review.
-
[Cancer immunotherapy using gammadelta T cells ex vivo expanded by bisphosphonate].Clin Calcium. 2008 Apr;18(4):499-505. Clin Calcium. 2008. PMID: 18379032 Review. Japanese.
Cited by
-
New Progress in Improving the Delivery Methods of Bisphosphonates in the Treatment of Bone Tumors.Drug Des Devel Ther. 2021 Dec 10;15:4939-4959. doi: 10.2147/DDDT.S337925. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34916778 Free PMC article. Review.
-
Combination of Detoxified Pneumolysin Derivative ΔA146Ply and Berbamine as a Treatment Approach for Breast Cancer.Mol Ther Oncolytics. 2020 Jun 24;18:247-261. doi: 10.1016/j.omto.2020.06.015. eCollection 2020 Sep 25. Mol Ther Oncolytics. 2020. PMID: 32728613 Free PMC article.
-
γδ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion.Front Immunol. 2018 Jun 15;9:1395. doi: 10.3389/fimmu.2018.01395. eCollection 2018. Front Immunol. 2018. PMID: 29963061 Free PMC article. Review.
-
Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy.Cancer Drug Resist. 2021 Jun 19;4(2):463-484. doi: 10.20517/cdr.2020.87. eCollection 2021. Cancer Drug Resist. 2021. PMID: 35582027 Free PMC article.
-
Cancer Nanomedicine Special Issue Review Anticancer Drug Delivery with Nanoparticles: Extracellular Vesicles or Synthetic Nanobeads as Therapeutic Tools for Conventional Treatment or Immunotherapy.Cancers (Basel). 2020 Jul 13;12(7):1886. doi: 10.3390/cancers12071886. Cancers (Basel). 2020. PMID: 32668783 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources